Grant: Project Grant
Université Laval
$753,525.00
Developing synthetic S100A9-based molecules for differentiation therapy of human acute myeloid leukemia
FY 2021-22
Summary
Acute myeloid leukemia is a type of blood cancer with very poor survival. We recently demonstrated that injections of a protein called S100A9 improves survival of mice with acute myeloid leukemia. We intend to develop a new treatment for acute myeloid leukemia based on the injection of S100A9 proteins. To develop this treatment, we will need to improve the stability of the S100A9 protein. We propose to develop mutated S100A9 proteins with increased stability, and to test these mutated proteins in mouse models of acute myeloid leukemia. These experiments will allow identifying a candidate drug for the treatment of acute myeloid leukemia.
Department
Program
Project Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
452826
Name
Tessier Philippe A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Developing synthetic S100A9-based molecules for differentiation therapy of human acute myeloid leukemia
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$753,525
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Animal Models; Drug Development; Leukemia; Myeloid Cells; Protein Structure; S100 Proteins
Abstract
Acute myeloid leukemia is a type of blood cancer with very poor survival. We recently demonstrated that injections of a protein called S100A9 improves survival of mice with acute myeloid leukemia. We intend to develop a new treatment for acute myeloid leukemia based on the injection of S100A9 proteins. To develop this treatment, we will need to improve the stability of the S100A9 protein. We propose to develop mutated S100A9 proteins with increased stability, and to test these mutated proteins in mouse models of acute myeloid leukemia. These experiments will allow identifying a candidate drug for the treatment of acute myeloid leukemia.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Tessier, Philippe A
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $753,525~ $0~
